Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX)

Harding Loevner, an asset management company, released its “Global Equity Strategy” third-quarter 2025 investor letter.  A copy of the letter can be downloaded here. The fund returned 2.62% gross (2.52% net) in the third quarter of 2025, compared to a 7.74% return for the MSCI All Country World Index and 7.36% gain for the MSCI World Index. YTD, the strategy rose 10.61% (net) compared to 18.86% and 17.83% for the indexes. The firm highlighted in the letter that the last six months represented one of the strongest momentum phases in over 70 years. Since the beginning of the year, high-momentum stocks have outperformed low-momentum stocks by a remarkable 45 percentage points, with much of the growth driven by advancements in AI. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its third-quarter 2025 investor letter, Harding Loevner Global Equity Strategy highlighted stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology company focusing on developing and commercializing therapies for treating cystic fibrosis (CF). The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 11.26%, and its shares gained 0.70% of their value over the last 52 weeks. On December 03, 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stock closed at $463.13 per share, with a market capitalization of $117.5 billion.

Harding Loevner Global Equity Strategy stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its third quarter 2025 investor letter:

“Health Care is the portfolio’s fourth-largest sector holding and one of its largest overweights. Our 11 Health Care companies span pharmaceuticals, biotechnology, life sciences, and equipment and services. They include Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a US company that has a near-monopoly position in cystic-fibrosis treatments and a research-and-development engine that offers optionality on future drugs; Vertex’s earnings should compound about 15% annually over the next five years.”

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 61 hedge fund portfolios held Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) at the end of the third quarter, which was 53 in the previous quarter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered $3.08 billion in revenue in the third quarter, representing a 11% growth compared to Q3 2024. While we acknowledge the risk and potential of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and shared the list of best large cap stocks to invest in for the long term. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.